PDCD1 and melanoma: For metastatic melanoma, eTILs > 12.2% in therapy-naïve samples correlated with improved progression-free survival (p = 0.037) and melanoma-specific survival (p = 0.0038) in patients receiving anti-PD-1-based immunotherapy [31].